AMPICILLIN SODIUM; SULBACTAM SODIUM - Generic Drug Details

What are the generic drug sources for ampicillin sodium; sulbactam sodium and what is the scope of patent protection?

Ampicillin sodium; sulbactam sodium is the generic ingredient in two branded drugs marketed by Acs Dobfar, Antibiotice, Astral, Eugia Pharma Speclts, Hikma, Hospira Inc, Hq Speclt Pharma, Istituto Bio Ita Spa, Medimetriks Pharms, Onesource Specialty, Sandoz, and Pfizer, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

Twelve suppliers are listed for this compound.

Summary for AMPICILLIN SODIUM; SULBACTAM SODIUM

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	25
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	4
Patent Applications:	982
DailyMed Link:	AMPICILLIN SODIUM; SULBACTAM SODIUM at DailyMed

Recent Clinical Trials for AMPICILLIN SODIUM; SULBACTAM SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The George Institute	PHASE3
Ain Shams University	PHASE2
DongGuk University

See all AMPICILLIN SODIUM; SULBACTAM SODIUM clinical trials

Pharmacology for AMPICILLIN SODIUM; SULBACTAM SODIUM

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for AMPICILLIN SODIUM; SULBACTAM SODIUM

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01CG	Beta-lactamase inhibitors
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for AMPICILLIN SODIUM; SULBACTAM SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	AMPICILLIN AND SULBACTAM	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	090646-001	Dec 21, 2011		DISCN	No	No
Hospira Inc	AMPICILLIN AND SULBACTAM	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	090375-001	Dec 21, 2011		DISCN	No	No
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-002	Dec 31, 1986	AP	RX	Yes	Yes

Market Dynamics and Financial Trajectory for Ampicillin Sodium and Sulbactam Sodium

Last updated: February 20, 2026

What are the Current Market Positions of Ampicillin Sodium and Sulbactam Sodium?

Ampicillin sodium is a broad-spectrum beta-lactam antibiotic widely used to treat urinary tract infections, respiratory infections, and bacterial sepsis. Sulbactam sodium is a beta-lactamase inhibitor often combined with beta-lactam antibiotics like ampicillin to combat resistant bacterial strains, especially Acinetobacter baumannii and Pseudomonas aeruginosa.

Market Share and Adoption Trends

• Global Market Size (2022): Estimated at $800 million for combined ampicillin and sulbactam products.
• Leading Regions: North America accounts for approximately 40% of sales, driven by hospital utilization and antibiotic stewardship policies. Europe follows with 25%, Asia-Pacific around 20%, and the rest of the world comprises the remaining 15%.
• Main Manufacturers: Pfizer, Sandoz (Novartis), Hikma Pharmaceuticals, and local generic producers, especially in India and China.

Sales Drivers

• Increasing antibiotic-resistant infections necessitate combination therapies like ampicillin plus sulbactam.
• Hospitals emphasize broad-spectrum antibiotics for empirical therapy.
• Generics capture 75% of the market, with branded versions reserved for specific formulations or formulations with extended indications.

What are the Key Factors Influencing Market Growth?

Rising Antibiotic Resistance

• Resistance to beta-lactam antibiotics is increasing globally. According to CDC data, beta-lactam resistance in E. coli and Klebsiella spp. rose by 15% between 2015 and 2020.
• Sulbactam’s role as a beta-lactamase inhibitor enhances efficacy against resistant strains, supporting sustained demand.

Regulatory Environment

• Regulatory agencies like FDA and EMA promote stewardship of broad-spectrum antibiotics to reduce resistance.
• Approvals for fixed-dose combinations (FDCs) and intravenous formulations influence market options.

Production and Supply Chain Dynamics

• Dominant production by established pharmaceutical companies limits price volatility.
• Manufacturing capacity expansion, particularly in Asia, affects supply stability.

Patent and Patent Expirations

• Most patents for original formulations expired between 2010-2020.
• New formulations or combination patents have limited protection, increasing generic market penetration.

How is the Financial Trajectory Evolving?

Revenue Trends

Year	Estimated Revenue (USD)	Growth Rate (%)	Market Share of Key Players
2022	$800 million	2.5% vs. 2021	Pfizer (25%), Sandoz (20%), Generics (30%)
2023	$820 million	2.5%	Similar distribution, with rising generics
2024	$835 million	1.8%	Slight slowdown, driven by patent cliffs and resistance issues
2025	$850 million	1.8%	Continued steady growth anticipated

Outlook for 2026-2030

• The compound annual growth rate (CAGR) is projected around 2% for the global market.
• Growth accelerates in emerging markets, where antibiotic resistance is increasing and healthcare spending is rising.
• Price erosion expected as generics dominate, but premium formulations or combination therapies may sustain margins.

What are the Competitive and Innovation Strategies?

Generic Expansion

• Most sales are from generics, with penetration expected to reach approximately 80% by 2030.
• Local manufacturers in India and China are expanding capacity to meet regional demand.

Novel Formulations and Combinations

• Development of fixed-dose combinations with enhanced pharmacokinetics.
• Liposomal and depot formulations in clinical development aim to improve patient compliance and efficacy.

Antimicrobial Stewardship

• Emphasis on targeted therapy reduces overuse, impacting sales volume.
• Hospitals favor diagnostics-driven prescriptions, potentially restricting broad-spectrum antibiotics like ampicillin-sulbactam.

What Are the Risks and Opportunities?

Risks

• Accelerating resistance could reduce clinical utility, prompting reformulations or new drug development.
• Strict regulatory policies and stewardship programs may limit market size.
• Price competition from generics exerts downward pressure on revenues.

Opportunities

• Growth in regions with less saturated markets, especially Asia-Pacific.
• Strategic alliances for new formulations and combinations.
• patent extensions or new indications could prolong market exclusivity.

Key Takeaways

• The combined market for ampicillin sodium and sulbactam sodium remains steady due to clinical demand against resistant bacteria.
• Growth is modest, averaging around 2% CAGR, mainly driven by emerging markets and resistance patterns.
• Generics dominate, limiting profit margins, although innovation efforts in formulations could provide differentiation.
• Resistance trends and regulatory trends will influence both supply and demand dynamics over the next five years.

FAQs

1. What factors could significantly alter the market for ampicillin and sulbactam? Increases in resistance or new competing antibiotics could reduce demand; alternatively, regulatory approvals for innovative formulations could boost sales.
2. Who are the main competitors in this market? Pfizer, Sandoz, Hikma, and numerous regional generic manufacturers.
3. Are there upcoming regulatory changes impacting these drugs? Yes. Antibiotic stewardship programs and new guidelines for antimicrobial use influence prescribing habits and approval processes.
4. What is the outlook for generic manufacturers? They will continue to capture the majority of the market, with expansion in emerging economies offsetting inherent pricing pressures.
5. How might new formulations affect market dynamics? Licensing and approval of novel delivery systems could command higher prices and extend patent protections, boosting profitability.

---

References

[1] Centers for Disease Control and Prevention. (2022). Antibiotic Resistance Threats in the United States. CDC.

[2] MarketWatch. (2022). Global Antibiotic Market Size 2022-2026. MarketWatch Reports.

[3] IQVIA. (2023). Global Antibiotics Market Data. IQVIA.

[4] FDA. (2020). Guidance for Industry: Antimicrobial Drug Development. U.S. Food and Drug Administration.

[5] European Medicines Agency. (2021). Information on Beta-lactam Antibiotics. EMA Publications.